BMTCN (BLOOD &Marrow Transplant
Certified Nurse) Exam Questions &
Answers | 100% Verified solutions
|Questions with Correct Answers 2026
latest update!!
autologous transplant (solid tumors malignant) - ANSWER neuroblastoma
sarcoma
germ cell tumors
brain tumors
breast cancer
ovarian cancer
melanoma
lung cancer
allogeneic transplant (malignant) - ANSWER acute lymphocytic leukemia
acute myeloid leukemia
chronic myeloid leukemia
myelodysplastic syndromes
non-hodgkin lymphoma
juvenile myelomonocytic leukemia
allogeneic transplant non malignant - ANSWER severe aplastic anemia
,Fanconi anemia
thalassemia
sickle cell disease
diamond blackfan anemia
cheduak-higashi syndrome
chronic granulomatous disease
congenital neutropenia
immunodeficiency non malignant allogeneic - ANSWER severe combined immunodeficiency
disease
wiskott-Aldrich syndrome
functional t cell deficiency
genetic non malignant allogeneic - ANSWER adrenoleukodystrophy
metachromatic leukodystrophy
hurler syndrome
hunter syndrome
gaucher sundrome
allogeneic non malignant - ANSWER osteopetrosis
Langerhans cell histiocytosis
glycogen storage diseases
example of myeloid cell - ANSWER monocytes
Hematopoiesis occurs primary in - ANSWER bone marrow
, graft versus tumor effect is promoted by - ANSWER withdrawal of immunosuppressive
therapy and administration of donor lymphocytes infusion
stem cells can be collected and kept in a facility that is accredited - ANSWER by the FACT
foundation for the accreditation of cellular therapy
advantage of autologus tansplant - ANSWER easily available source of stem cells
decreased risk of side effects
early engraftment
low risk of graft versus host disease (gvhd)
the testing for allorgeneic - ANSWER is done to determine the strength of match through
human leukocytes antigen (hla) antigen
the higher the degree of mismatch - ANSWER the greater the like hood that the recipient
will develop life threatening complications such as GVHD
haploidentical - ANSWER half-matched related
advantage for allogeneic transplant - ANSWER disease-free stem cell source
potential for gvt effect
synegeneic - ANSWER hsct use the stem cells of an identical twin ( same hla tping)
, DLI donor lyphocyte infusion - ANSWER infusion of lymphocytes from the original donor
given the setting of relapsed disease after allogeneic transplant. this is for the immune system
to fight the tumor inducing a gvt effect.
eligibility criteria for hsct - ANSWER comorbidities
stage of cancer
performance status
donor availability
first criterion to determine eligibility - ANSWER if pt's disease is chemotherapy-sensitive
(more concern with autologous )
acceptable organ function and is free of life-threatening viral exposures or diseases
pt compliance with regimen as well as support system
chemistry panel - ANSWER electrolytes
liver and kidney function test
multiple infectious diseases - ANSWER hep B,C
HIV
Human T-cell leukemia virus type 1
cytomegalovirus
herpes simplex virus and varicella zoster virus
health literacy - ANSWER the degree to which an individual has the capacity of obtain,
communicate, process and understand basic health information and services to make
appropriate health decision.
Certified Nurse) Exam Questions &
Answers | 100% Verified solutions
|Questions with Correct Answers 2026
latest update!!
autologous transplant (solid tumors malignant) - ANSWER neuroblastoma
sarcoma
germ cell tumors
brain tumors
breast cancer
ovarian cancer
melanoma
lung cancer
allogeneic transplant (malignant) - ANSWER acute lymphocytic leukemia
acute myeloid leukemia
chronic myeloid leukemia
myelodysplastic syndromes
non-hodgkin lymphoma
juvenile myelomonocytic leukemia
allogeneic transplant non malignant - ANSWER severe aplastic anemia
,Fanconi anemia
thalassemia
sickle cell disease
diamond blackfan anemia
cheduak-higashi syndrome
chronic granulomatous disease
congenital neutropenia
immunodeficiency non malignant allogeneic - ANSWER severe combined immunodeficiency
disease
wiskott-Aldrich syndrome
functional t cell deficiency
genetic non malignant allogeneic - ANSWER adrenoleukodystrophy
metachromatic leukodystrophy
hurler syndrome
hunter syndrome
gaucher sundrome
allogeneic non malignant - ANSWER osteopetrosis
Langerhans cell histiocytosis
glycogen storage diseases
example of myeloid cell - ANSWER monocytes
Hematopoiesis occurs primary in - ANSWER bone marrow
, graft versus tumor effect is promoted by - ANSWER withdrawal of immunosuppressive
therapy and administration of donor lymphocytes infusion
stem cells can be collected and kept in a facility that is accredited - ANSWER by the FACT
foundation for the accreditation of cellular therapy
advantage of autologus tansplant - ANSWER easily available source of stem cells
decreased risk of side effects
early engraftment
low risk of graft versus host disease (gvhd)
the testing for allorgeneic - ANSWER is done to determine the strength of match through
human leukocytes antigen (hla) antigen
the higher the degree of mismatch - ANSWER the greater the like hood that the recipient
will develop life threatening complications such as GVHD
haploidentical - ANSWER half-matched related
advantage for allogeneic transplant - ANSWER disease-free stem cell source
potential for gvt effect
synegeneic - ANSWER hsct use the stem cells of an identical twin ( same hla tping)
, DLI donor lyphocyte infusion - ANSWER infusion of lymphocytes from the original donor
given the setting of relapsed disease after allogeneic transplant. this is for the immune system
to fight the tumor inducing a gvt effect.
eligibility criteria for hsct - ANSWER comorbidities
stage of cancer
performance status
donor availability
first criterion to determine eligibility - ANSWER if pt's disease is chemotherapy-sensitive
(more concern with autologous )
acceptable organ function and is free of life-threatening viral exposures or diseases
pt compliance with regimen as well as support system
chemistry panel - ANSWER electrolytes
liver and kidney function test
multiple infectious diseases - ANSWER hep B,C
HIV
Human T-cell leukemia virus type 1
cytomegalovirus
herpes simplex virus and varicella zoster virus
health literacy - ANSWER the degree to which an individual has the capacity of obtain,
communicate, process and understand basic health information and services to make
appropriate health decision.
